Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease?

× No keyword cloud information.

12 in total

1. Use of ibuprofen and risk of Parkinson disease.

Authors: Xiang Gao; Honglei Chen; Michael A Schwarzschild; Alberto Ascherio
Journal: Neurology Date: 2011-03-02 Impact factor: 9.910

Review 2. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis.

Authors: Joshua J Gagne; Melinda C Power
Journal: Neurology Date: 2010-03-23 Impact factor: 9.910

Review 3. Innate and adaptive immune responses in Parkinson's disease.

Authors: Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal: Prog Brain Res Date: 2019-12-05 Impact factor: 2.453

Review 4. Neuroinflammatory responses in Parkinson's disease: relevance of Ibuprofen in therapeutics.

Authors: Ashish Singh; Pratibha Tripathi; Sarika Singh
Journal: Inflammopharmacology Date: 2020-10-14 Impact factor: 4.473

5. Reduction of nuclear peroxisome proliferator-activated receptor gamma expression in methamphetamine-induced neurotoxicity and neuroprotective effects of ibuprofen.

Authors: Takeshi Tsuji; Masato Asanuma; Ikuko Miyazaki; Ko Miyoshi; Norio Ogawa
Journal: Neurochem Res Date: 2008-10-23 Impact factor: 3.996

Review 6. Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease?

Authors: Anna R Carta; Augusta Pisanu
Journal: Neurotox Res Date: 2012-08-07 Impact factor: 3.911

Review 7. NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies.

Authors: Ali Samii; Mahyar Etminan; Matthew O Wiens; Siavash Jafari
Journal: Drugs Aging Date: 2009 Impact factor: 3.923

8. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Authors: Francesca L'Episcopo; Cataldo Tirolo; Salvatore Caniglia; Nunzio Testa; Pier A Serra; Francesco Impagnatiello; Maria C Morale; Bianca Marchetti
Journal: J Neuroinflammation Date: 2010-11-23 Impact factor: 8.322

Review 9. Advances in non-dopaminergic treatments for Parkinson's disease.

Authors: Sandy Stayte; Bryce Vissel
Journal: Front Neurosci Date: 2014-05-22 Impact factor: 4.677

10. Aging, rather than Parkinson's disease, affects the responsiveness of PBMCs to the immunosuppression of bone marrow mesenchymal stem cells.

Authors: Yun-Qian Guan; Chun-Song Zhao; Hai-Qiang Zou; Xiao-Ming Yan; Lu-Lu Luo; Jia-Lin Wu; Xiaobo Li; Yu Alex Zhang
Journal: Mol Med Rep Date: 2018-11-19 Impact factor: 2.952